Media Articles Related to Zolinza (Vorinostat)
ASH 2013: Big Year for CLL, Lymphoma
Source: Medscape Hematology-Oncology Headlines [2013.11.25]
Highlighting major studies and a plethora of new drugs, Dr. Bruce Cheson predicts that ASH 2013 will be a big year for non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia.
Low-intensity therapy for Burkitt lymphoma found to be highly effective
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2013.11.15]
Adult patients with a type of cancer known as Burkitt lymphoma had excellent long-term survival rates - upwards of 90 percent - following treatment with low-intensity chemotherapy regimens, according to a new clinical trial finding.
Imbruvica Approved for Mantle Cell Lymphoma
Source: MedicineNet Anemia Specialty [2013.11.14]
Title: Imbruvica Approved for Mantle Cell Lymphoma
Category: Health News
Created: 11/13/2013 4:35:00 PM
Last Editorial Review: 11/14/2013 12:00:00 AM
Study evaluates early stem cell transplants for non-Hodgkin's lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2013.11.04]
Performing early stem cell transplants in patients with aggressive non-Hodgkin's lymphoma does not improve overall survival in high-risk patients, according to a study published in the New England Journal of Medicine.But early transplantation does appear to be beneficial among a small group of patients who are at the very highest risk, the study found.
Online lymphoma community 'The Lymphoma Hub' just launched
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2013.11.02]
Led by La Fondazione Italiana Linfomi (FIL), a non-profit Italian professional lymphoma research organization, and supported by an unrestricted educational grant from Celgene Corporation, the Lymphoma Hub has been launched as a new online community for hematologists and oncologists treating lymphoma.
Published Studies Related to Zolinza (Vorinostat)
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. [2010.07]
Histone deacetylase inhibitors (HDACi) affect chromatin remodelling and modulate the expression of aberrantly silenced genes. HDACi have single-agent clinical activity in haematological malignancies and have synergistic anti-leukaemia activity when combined with anthracyclines in vitro... The combination of vorinostat and idarubicin is generally tolerable and active in patients with advanced leukaemia and should be studied in the front-line setting.
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. [2010.01.01]
PURPOSE Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by both histone and nonhistone-mediated mechanisms...
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for
first-line therapy of advanced non-small-cell lung cancer. 
PURPOSE Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by
both histone and nonhistone-mediated mechanisms...
A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. [2009.11.15]
CONCLUSIONS: Administration of a single supratherapeutic dose of the histone deacetylase inhibitor vorinostat is not associated with prolongation of the QTc interval. A dedicated QTc study in advanced cancer patients is a robust means for assessing risk for ventricular repolarization prolongation.
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. [2011.11.12]
Purpose Combining proteasome and histone deacetylase (HDAC) inhibition has been seen to provide synergistic anti-tumor activity, with complementary effects on a number of signaling pathways. The novel bi-cyclic structure of marizomib with its unique proteasome inhibition, toxicology and efficacy profiles, suggested utility in combining it with an HDAC inhibitor such as vorinostat...
Clinical Trials Related to Zolinza (Vorinostat)
Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma [Not yet recruiting]
1. Rationale In mantle cell lymphoma, the conventional chemotherapy achieves only
temporary responses with a median duration of remissions only from 1 to 2 years.
Therefore, mantle cell lymphoma is known as one of the B-cell lymphomas with poor
prognosis. Although the treatment outcome of mantle cell lymphoma has been improved
since intensive chemotherapy regimens such as HyperCVAD was used, a substantial number
of patients are still frequently relapsed after chemotherapy. After relapse, most of
them became refractory to various kinds of salvage treatment. That is why the results
of most salvage chemotherapy regimens were disappointing. In addition, mantle cell
lymphoma generally occurs in elderly people. Thus, intensive salvage chemotherapy may
not be feasible for elderly patients. Therefore, an effective, novel combination
treatment is urgently needed in relapsed or refractory mantle cell lymphoma patients.
- Vorinostat will produce synergism with a combination treatment regimen
(Fludarabine, mitoxantrone, dexamethasone, FND) without overlapping toxicity
- Vorinostat maintenance treatment will reduce the relapse rate in patients
ineligible for autologous stem cell transplantation.
3. Purpose A phase II investigation to determin the effectiveness of vorinostat in
combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients
with relapsed or refractory mantle cell lymphomain patients with relapsed or refractory
mantle cell lymphoma.
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma [Recruiting]
The goal of this clinical research study is to find out how well the drug Zolinza
(vorinostat) works in combination with the drug combination called CHOP (cyclophosphamide,
doxorubicin, vincristine, and prednisone) to treat patients with untreated T-cell NHL. The
safety of these drugs in combination and the best dose of vorinostat when given in
combination with CHOP will also be studied.
1. Determine the toxicity profile and the maximum tolerated dose (MTD) of vorinostat when
administered in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
2. To evaluate the progression free survival for patients with T-cell NHL receiving the
combination of vorinostat and CHOP
Secondary Objectives (Phase I and II):
1. To evaluate the response rate for patients with T-cell NHL receiving the combination of
vorinostat and CHOP.
2. To assess overall survival in patients with T-cell NHL treated with the combination of
vorinostat and CHOP.
Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer [Recruiting]
There is scientific rationale for exploring the role of vorinostat, histone deacetylase
inhibitor with capecitabine (X) and cisplatin (P), one of standard chemotherapy in patients
with advanced gastric cancer. XP is a new standard of care in advanced gastric cancer (AGC)
and vorinostat is a novel targeted agent that prevents tumor cell proliferation, survival
and angiogenesis through histone deacetylase inhibition.
High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors [Recruiting]
This randomized clinical trial is studying high-dose or low-dose vorinostat in combination
with carboplatin or paclitaxel to see how well it works in treating patients with advanced
solid tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work
in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Giving different doses of vorinostat together with carboplatin
or paclitaxel may kill more tumor cells
Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma [Recruiting]
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill
tumor cells. Giving vorinostat together with chemotherapy and radiation therapy may kill
more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when
given together with cisplatin and radiation therapy in treating patients with stage III or
stage IVa squamous cell cancer of the oropharynx which is either unresectable or borderline
Reports of Suspected Zolinza (Vorinostat) Side Effects
Decreased Appetite (12),
Pleural Effusion (8),
Febrile Neutropenia (8),
Disease Progression (6),
White Blood Cell Count Decreased (6),
Renal Failure (6), more >>